Table 1. Baseline characteristics of donors, non-responders and responders included in the study.
| Donorsa (n=6) | Non-responders (n=22) | Responders (n=12) | P-value | |
|---|---|---|---|---|
| Median age, years (IQR) | 26.7 (25.5–36.2) | 40.5 (28.5–47.0) | 44 (36.0–57.5) | 0.03b |
| Male sex, n (%) | 5 (83.3) | 11 (50) | 5 (41.6) | 0.73 |
| Median disease duration (years (range)) | — | 7.0 (1–27) | 11.5 (0–27) | 0.19 |
| Extent of disease, n (%) | — | 1.0 | ||
| E1, proctitis | 0 (0) | 0 (0) | ||
| E2, left-sided | 11 (50.0) | 6 (50.0) | ||
| E3, pancolitis | 11 (50.0) | 6 (50.0) | ||
| Concomitant drug treatment, n (%) | — | |||
| Mesalamine oral | 16 (66.7) | 8 (66.7) | 1.0 | |
| Mesalamine/corticosteroid rectal | 5 (20.8) | 4 (33.3) | 0.69 | |
| Immunosuppressants | 7 (29.2) | 4 (33.3) | 1.0 | |
| Systemic corticosteroids <10 mg per day | 4 (16.7) | 3 (25.0) | 0.66 | |
| Median SCCAI score at inclusion (range) | — | 8 (4–11) | 9 (4–11) | 0.77 |
| Mayo endoscopic score at inclusion, n (%) | ||||
| Mayo 1 | 3 (13.6) | 2 (16.7) | 0.34 | |
| Mayo 2 | 12 (54.5) | 9 (75.0) | ||
| Mayo 3 | 7 (31.8) | 1 (8.3) | ||
| Site of disease at inclusion, n (%) | ||||
| Rectum only | — | 3 (13.6) | 1 (8.3) | 0.42 |
| Left side of colon | 13 (59.1) | 10 (83.3) | ||
| Proximal to the splenic flexure | 6 (27.3) | 1 (8.3) | ||
| Allocated to FMT-D, n (%) | — | 10 (45.5) | 7 (58.3) | 0.72 |
Abbreviations: FMT, faecal microbiota transplantation; FMT-D, FMT with donor faeces; FU, follow-up; SCCAI, Simple Clinical Colitis Activity Index.
There was no significant difference in age between non-responders and responders (P=0.194) and donors and non-responders (P=0.065).
Extent of disease was scored according to the Montreal classification. The Mayo endoscopic score was assessed at the baseline sigmoidoscopy.
a
Donors from responders were selected as healthy controls for comparisons.
b
Donors were significantly younger than responders (P=0.009).